Literature DB >> 23616161

Varicella-zoster virus acute myelitis in a patient with MS treated with natalizumab.

Jennifer Yeung1, Cécile Cauquil, Guillaume Saliou, Ghaida Nasser, Sophio Rostomashvili, David Adams, Marie Théaudin.   

Abstract

We report a case of varicella-zoster virus (VZV) myelitis in a woman with relapsing-remitting multiple sclerosis (RRMS) receiving natalizumab, a humanized monoclonal antibody that induces an immunosuppression localized to the CNS.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23616161      PMCID： PMC3719426          DOI： 10.1212/WNL.0b013e3182918d27

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


  5 in total

1.  Natalizumab and HSV meningitis.

Authors:  Erica Seiguer Shenoy; Eleftherios Mylonakis; Rocio M Hurtado; Nagagopal Venna
Journal:  J Neurovirol       Date:  2011-04-13       Impact factor: 2.643

2.  Herpes encephalitis during natalizumab treatment in multiple sclerosis.

Authors:  A Kwiatkowski; J Gallois; N Bilbault; G Calais; A Mackowiak; P Hautecoeur
Journal:  Mult Scler       Date:  2011-11-02       Impact factor: 6.312

3.  Varicella zoster virus encephalitis during treatment with anti-tumor necrosis factor-alpha agent in a psoriatic arthritis patient.

Authors:  Giovanni Buccoliero; Gaetano Lonero; Chiara Romanelli; Pietro Loperfido; Francesco Resta
Journal:  New Microbiol       Date:  2010-07       Impact factor: 2.479

4.  Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial.

Authors:  Edward C Keystone; Arthur F Kavanaugh; John T Sharp; Hyman Tannenbaum; Ye Hua; Leah S Teoh; Steven A Fischkoff; Elliot K Chartash
Journal:  Arthritis Rheum       Date:  2004-05

5.  Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy.

Authors:  Eric Vickrey; Sharon Allen; Jayesh Mehta; Seema Singhal
Journal:  Cancer       Date:  2009-01-01       Impact factor: 6.860
  5 in total
  9 in total

Review 1.  Vaccines in Multiple Sclerosis.

Authors:  Eric M L Williamson; Salim Chahin; Joseph R Berger
Journal:  Curr Neurol Neurosci Rep       Date:  2016-04       Impact factor: 5.081

Review 2.  Infections in Patients Receiving Multiple Sclerosis Disease-Modifying Therapies.

Authors:  Elena Grebenciucova; Amy Pruitt
Journal:  Curr Neurol Neurosci Rep       Date:  2017-09-22       Impact factor: 5.081

Review 3.  Neurological complications of varicella zoster virus reactivation.

Authors:  Maria A Nagel; Don Gilden
Journal:  Curr Opin Neurol       Date:  2014-06       Impact factor: 5.710

4.  Varicella Zoster Virus Induces Nuclear Translocation of the Neurokinin-1 Receptor, Promoting Lamellipodia Formation and Viral Spread in Spinal Astrocytes.

Authors:  Andrew N Bubak; Christina N Como; Anna M Blackmon; Seth Frietze; Teresa Mescher; Dallas Jones; Randall J Cohrs; Petr Paucek; Nicholas L Baird; Maria A Nagel
Journal:  J Infect Dis       Date:  2018-09-08       Impact factor: 5.226

Review 5.  Infectious Complications of Novel Multiple Sclerosis Therapies.

Authors:  S N Levin; T B Kaplan
Journal:  Curr Infect Dis Rep       Date:  2017-02       Impact factor: 3.725

Review 6.  Infection risk in patients on multiple sclerosis therapeutics.

Authors:  Eric M Williamson; Joseph R Berger
Journal:  CNS Drugs       Date:  2015-03       Impact factor: 5.749

7.  Longitudinally extensive transverse myelitis with anti-NMDA receptor antibodies during a systemic lupus erythematosus flare-up.

Authors:  Kentarou Takei; Mineshige Sato; Masashi Nakamura; Hiroshi Shimizu
Journal:  BMJ Case Rep       Date:  2015-11-26

Review 8.  Neuroimaging of Natalizumab Complications in Multiple Sclerosis: PML and Other Associated Entities.

Authors:  Justin M Honce; Lidia Nagae; Eric Nyberg
Journal:  Mult Scler Int       Date:  2015-09-21

Review 9.  Determinants of neurological syndromes caused by varicella zoster virus (VZV).

Authors:  Peter Ge Kennedy; Trine H Mogensen
Journal:  J Neurovirol       Date:  2020-06-03       Impact factor: 2.643
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.